Development of an Investigational New Drug for the treatment of pancreatic cancer

A small UK biotech company, Sentinel Oncology, is working to identify a new drug specifically for pancreatic cancer—a disease with almost no effective treatments currently available. This matters because pancreatic cancer has an extremely poor prognosis, and the few existing treatment options offer limited benefit. While the number of cancer drugs has grown overall, pancreatic cancer has been left behind. The company aims to fill this gap by designing a molecule that can be tested in humans. If the project succeeds, clinicians will be able to launch clinical trials combining this new drug with current standard-of-care treatments. The goal is to safely boost the anti-cancer effects of those existing therapies, potentially improving survival and quality of life for patients who currently have few choices. This is not a cure, but a step toward making existing treatments work better for a disease that urgently needs new options. The research is applied and directly aimed at reaching patients through clinical testing.